Sanofi/GSK Arixtra Adds DVT, Pulmonary Embolism Treatment Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
Expanded indication comes as Sanofi prepares to divest Arixtra to GlaxoSmithKline in connection with its proposed acquisition of Lovenox-maker Aventis.
You may also be interested in...
Phase III Trial For Sanofi Anti-Clotting Drug Halted Due To Excess Bleeding
Sanofi-Aventis’ idraparinux demonstrated noninferiority versus vitamin K antagonists but was associated with more bleeding, according to Lancet article.
Phase III Trial For Sanofi Anti-Clotting Drug Halted Due To Excess Bleeding
Sanofi-Aventis’ idraparinux demonstrated noninferiority versus vitamin K antagonists but was associated with more bleeding, according to Lancet article.
Sanofi Extends Aventis Offer To June 30
The extension would just meet Sanofi’s goal to close the Aventis merger in the second quarter. The European Commission approved sale of Arixtra and Fraxiparine to GlaxoSmithKline May 26; FTC decision on merger is pending.